Detalhe da pesquisa
1.
Pharmacokinetics of serelaxin in patients with hepatic impairment: a single-dose, open-label, parallel group study.
Br J Clin Pharmacol
; 79(6): 937-45, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25511105
2.
Assessment of the Immunogenicity Potential for Oligonucleotide-Based Drugs.
Nucleic Acid Ther
; 32(5): 369-377, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36178478
3.
Pharmacokinetics of serelaxin in patients with severe renal impairment or end-stage renal disease requiring hemodialysis: A single-dose, open-label, parallel-group study.
J Clin Pharmacol
; 56(4): 474-83, 2016 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-26239266
4.
Safety and tolerability of serelaxin, a recombinant human relaxin-2 in development for the treatment of acute heart failure, in healthy Japanese volunteers and a comparison of pharmacokinetics and pharmacodynamics in healthy Japanese and Caucasian populations.
J Clin Pharmacol
; 55(4): 415-22, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25408331
5.
Reduction of matrix interferences by the combination of chaotropic salt and DMSO in a broadly applicable target-based ELISA for pharmacokinetic studies of therapeutic monoclonal antibodies.
J Pharm Biomed Anal
; 50(5): 924-31, 2009 Dec 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-19608373
6.
HIV TAT basic peptide is not a high-affinity ligand for VEGF receptor 2.
Biol Chem
; 384(10-11): 1435-41, 2003.
Artigo
em Inglês
| MEDLINE | ID: mdl-14669986